Broken String Biosciences team will attend three key industry events across Singapore and the US next month, including ISCT Asia in Singapore on 2–5 September, UCSD Gene Therapy Initiative Symposium in San Diego on 16–17 September, and the 7th Genome Editing Therapeutics Summit in Boston on 29–30 September.
Published
Signal category
Presence & Recognition
Quote
“Our team will be attending three key industry events across Singapore and the US next month.”
— Broken String Biosciences team
Company
Broken String Biosciences
Powering the future of gene editing development.
- Industry
- Biotechnology Research
- Location
- Little Chesterford, GB
- Company size
- 35 employees
Broken String Bioscience’s technology platform, INDUCE-seq®, supports the development of cell and gene therapies that are safer by design. INDUCE-seq®, is an NGS-based DNA break mapping platform that enables companies developing cell and gene therapies to measure and quantify the specificity of off-target genetic edits and evaluate the associated genetic outcomes. The platform provides data-driven, actionable insights across the discovery, pre-clinical and clinical development stages to advance gene editing programs.